NICE should speak up on rosiglitazone
I am very pleased with the new drug guidelines from NICE ('Gliptins given key diabetes role', pulsetoday.co.uk/news).
The institute is to be congratulated in devising an algorithm for health professionals in treatment of type 2 diabetes, with recommendations for both glitazones and gliptins second-line where there are concerns regarding hypoglycaemia.
It is a shame, however, that NICE was unable to give a clear lead on the continuing controversy of cardiovascular safety of rosiglitazone, which is tarnishing the image of the glitazones as a class.
From Professor Anthony Barnett, professor of medicine and honorary consultant physician at the University of Birmingham